SecBot SecBot
PRESS-RELEASE ·Filed Apr 16, 2026

TRVI

Trevi Therapeutics, Inc.
NEUTRAL
Impact 6/10
Horizonimmediate Processed7mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

The capital raise provides Trevi with additional funding for clinical development of Haduvio™, but investors should monitor for share dilution. The stock may react negatively in the near term due to dilution, especially given the lack of revenue or earnings from a still-clinical-stage company.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.23
T+0 close · Apr 16, 2026 · via day close
Latest settled
+17.60%
T+60 · $17.91
Vs SPY
+11.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $15.23entry
  2. T+1 · 7mo ago +1.12%α +1.31% · $15.40
  3. T+5 · 7mo ago −5.38%α −5.94% · $14.41
  4. T+20 · 6mo ago −0.98%α −6.36% · $15.08
  5. T+60 · 4mo ago +17.60%α +11.45% · $17.91
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Trevi Therapeutics priced an underwritten public offering of 11,600,000 shares at $13.00 per share, raising approximately $150 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 1,740,000 shares. The offering is expected to close on or about April 20, 2026, subject to customary conditions.

Key Financial Metrics

Deal Value
$150.0M

Key Facts

  • Trevi Therapeutics is offering 11,600,000 shares of common stock at $13.00 per share.
  • Total gross proceeds are approximately $150 million, before underwriting discounts and expenses.
  • Underwriters have a 30-day option to purchase up to 1,740,000 additional shares.
  • The offering is expected to close around April 20, 2026, subject to customary closing conditions.
  • Morgan Stanley, Leerink Partners, Cantor, and Stifel are joint book-running managers.

Financial Impact

$150 million in gross proceeds from issuance of 11.6M shares at $13.00 per share, with potential for additional $22.6 million if the overallotment is exercised.

dilutioncashequity

Risk Factors

  • Dilution to existing shareholders upon issuance of new shares.
  • Uncertainty around market reception of the offering given current market conditions and the company's pre-revenue status.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3275929

Track record

12 reports on TRVI

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +15.38% at T+60 after the Mar 9, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $14.91 Now $13.29 −10.87% settles Dec 9
  2. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $13.52 Now $13.29 −1.70% settles Nov 25
  3. Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
  4. Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $13.46 to $18.40 Now $13.29 −1.26% ▲ +36.70% +34.81% vs SPY
  5. Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $14.80 to $13.24 Now $13.29 −10.20% ▼ −10.54% −13.71% vs SPY
  6. Apr 20, 202630w ago Press Release Neutral 5/10 Entry $14.62 to $13.43 Now $13.29 −9.10% ▼ −8.14% −13.05% vs SPY
  7. Apr 17, 202630w ago 424B5 Bearish 7/10 Entry $15.40 to $13.43 Now $13.29 +13.70% ▲ +12.79% +16.99% vs SPY
  8. Apr 17, 202630w ago 8-K Bearish 7/10 Entry $15.23 to $15.08 Now $13.29 +12.74% ▲ +0.98% +6.36% vs SPY
  9. Apr 16, 202630w ago Press Release Neutral 6/10 Viewing Entry $15.23 to $15.08 Now $13.29 −12.74% ▼ −0.98% −6.36% vs SPY
  10. Mar 17, 202634w ago Press Release Mixed 6/10 Entry $10.69 to $14.54 Now $13.29 +24.32% ▲ +36.02% +29.97% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026